NASDAQ:DARE - Dare Bioscience Stock Price, Forecast & News

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Dare Bioscience Inc (NASDAQ:DARE) announced its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.01. View Dare Bioscience's Earnings History.

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Dare Bioscience.

2 equities research analysts have issued twelve-month price objectives for Dare Bioscience's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Dare Bioscience's share price to reach $3.00 in the next year. This suggests a possible upside of 80.7% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Press coverage about DARE stock has been trending very negative on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dare Bioscience earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Dare Bioscience.

Dare Bioscience saw a increase in short interest in December. As of December 31st, there was short interest totalling 649,000 shares, an increase of 5.8% from the December 15th total of 613,500 shares. Based on an average daily volume of 252,000 shares, the short-interest ratio is currently 2.6 days. Currently, 3.9% of the company's stock are short sold. View Dare Bioscience's Current Options Chain.

Some companies that are related to Dare Bioscience include Aduro BioTech (ADRO), Stealth BioTherapeutics (MITO), Axovant Gene Therapies (AXGT), AVEO Pharmaceuticals (AVEO), Bellicum Pharmaceuticals (BLCM), Sesen Bio (SESN), Scpharmaceuticals (SCPH), Aquestive Therapeutics (AQST), Synlogic (SYBX), Immunic (IMUX), Proteostasis Therapeutics (PTI), TFF Pharmaceuticals (TFFP), Inflarx (IFRX), Trevi Therapeutics (TRVI) and Cyclerion Therapeutics (CYCN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dare Bioscience investors own include FuelCell Energy (FCEL), Synergy Pharmaceuticals (SGYP), BIOLINERX LTD/S (BLRX), Novavax (NVAX), CytRx (CYTR), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Tonix Pharmaceuticals (TNXP), AEterna Zentaris (AEZS) and Heat Biologics (HTBX).

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DARE stock can currently be purchased for approximately $1.66.

Dare Bioscience has a market capitalization of $27.69 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.View Additional Information About Dare Bioscience.

The official website for Dare Bioscience is http://www.darebioscience.com/.

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]